title: Comparison of angiographic and IVUS follow-up between the two different drug-eluting stents implanted simultaneously in the same individuals.
abstract: BACKGROUND
  While, theoretically, a drug-eluting stent (DES) with a biodegradable polymer should reduce the incidence of late in-stent thrombosis, this has not been experimentally tested.
  
  
  OBJECTIVE
  This study compared long-term manifestations of the Excel DES, with a biodegradable polymer, to the Endeavor DES, with a biocompatible polymer, in the same individuals.
  
  
  METHODS
  Forty-eight patients underwent simultaneous implantation of 1 or more Endeavor stents and 1 or more Excel stents, during the same procedure, and were evaluated with coronary angiography and intravascular ultrasound (IVUS) at least 1 year postprocedure. Within-patient comparisons were made between the Excel- and Endeavor-stented segments for efficacy and safety.
  
  
  RESULTS
  A total of 131 stents (69 Endeavor stents and 62 Excel stents) were implanted in 98 lesions among 48 patients. Baseline characteristics of the lesions in the two stented segments groups were comparable. Average follow-up duration was 14.3 ± 2.5 months. In-stent late luminal loss and luminal stenosis were higher in Endeavor-stented segments than in Excel-stented segments (P<.01). The binary restenosis rate was slightly higher in Endeavor-stented segments (4.3% vs. 1.6%; P=.379). In-stent thrombosis, late incomplete stent apposition, and uncovered stent struts were higher in Excel-stented segments than in Endeavor-stented segments (P<.01). There was 1 case of an in-stent coronary aneurysm with an Excel-stented segment. Four segments, in 4 cases (2 in each stent group), required target lesion revascularization.
  
  
  CONCLUSIONS
  This study suggested that, compared to DESs with a biocompatible polymer, DESs with biodegradable polymer do not appear to present an advantage for long-term safety.
authors.affiliation: Liuhuaqiao Hospital, Department of Cardiology, #111, Liuhua Rd, Guangzhou, Guangdong 510010, China. dcxiang@foxmail.com
authors.forename: Dingcheng
authors.initials: D
authors.lastname: Xiang
authors.forename: Shaodong
authors.initials: S
authors.lastname: Yi
authors.forename: Yunjun
authors.initials: Y
authors.lastname: Ruan
authors.forename: Zhihua
authors.initials: Z
authors.lastname: Gong
authors.forename: Changjiang
authors.initials: C
authors.lastname: Hong
authors.forename: Jian
authors.initials: J
authors.lastname: Qiu
mesh_terms: D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D001672:Biocompatible Materials / Q000627:therapeutic use; D057186:Comparative Effectiveness Research; D017023:Coronary Angiography / Q000379:methods*; D003324:Coronary Artery Disease / Q000175:diagnosis / Q000503:physiopathology; D023903:Coronary Restenosis / Q000000981:diagnostic imaging / Q000517:prevention & control; D003331:Coronary Vessels / Q000000981:diagnostic imaging / Q000503:physiopathology; D054855:Drug-Eluting Stents / Q000009:adverse effects / Q000592:standards; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D062645:Percutaneous Coronary Intervention / Q000009:adverse effects / Q000379:methods; D011108:Polymers / Q000627:therapeutic use; D011183:Postoperative Complications / Q000000981:diagnostic imaging / Q000517:prevention & control; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D016896:Treatment Outcome; D018084:Ultrasonography, Interventional / Q000379:methods*
chemical_list: D000903:Antibiotics, Antineoplastic; D001672:Biocompatible Materials; D011108:Polymers; C489443:zotarolimus; D020123:Sirolimus